LYTIR

Company · STOK

Stoke Therapeutics, Inc.

Nasdaq's symbol directory lists STOK on Nasdaq as “Stoke Therapeutics, Inc. - Common Stock”.

In the 12 months to Nov 8, 2026: insiders sold on 10 occasions ($1.5M); 2 planned-sale notices; 5 filings by holders of 5% or more; 2 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC · Appeared in No. 33, No. 32, No. 31, No. 30, No. 29

Insider purchases and sales, by month (last 12 months)Insider purchases: $0 in total; Insider sales: $1.5M in total.Jun: Insider sales $44KJul: Insider sales $236KAug: Insider sales $855KSep: Insider sales $170KOct: Insider sales $44KNov: Insider sales $190KDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $0Insider sales below: $1.5M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Ticho Barry, CHIEF MEDICAL OFFICER sold on 6 days 5 of them under a 10b5-1 plan latest Nov 2, 2026 sold $985K
  2. Kaye Edward M. MD sold on 1 day latest Aug 18, 2026 sold $403K
  3. Allan Jonathan, GENERAL COUNSEL & CORP SEC sold on 3 days 2 of them under a 10b5-1 plan latest Oct 2, 2026 sold $152K
Every trade (10)
  1. SELLTicho Barry, CHIEF MEDICAL OFFICER sold Nov 2, 2026 7,195 shares 2 legs combined 10b5-1 plan (scheduled) filing $190K
  2. SELLAllan Jonathan, GENERAL COUNSEL & CORP SEC sold Oct 2, 2026 627 shares 10b5-1 plan (scheduled) filing $17K
  3. SELLTicho Barry, CHIEF MEDICAL OFFICER sold Oct 1, 2026 1,051 shares 10b5-1 plan (scheduled) filing $27K
  4. SELLTicho Barry, CHIEF MEDICAL OFFICER sold Sep 1, 2026 5,545 shares 2 legs combined 10b5-1 plan (scheduled) filing $170K
  5. SELLKaye Edward M. MD sold Aug 18, 2026 12,567 shares 2 legs combined filing $403K
  6. SELLTicho Barry, CHIEF MEDICAL OFFICER sold Aug 18, 2026 4,767 shares 2 legs combined filing $153K
  7. SELLAllan Jonathan, GENERAL COUNSEL & CORP SEC sold Aug 18, 2026 2,861 shares 2 legs combined filing $92K
  8. SELLTicho Barry, CHIEF MEDICAL OFFICER sold Aug 3, 2026 7,176 shares 2 legs combined 10b5-1 plan (scheduled) filing $208K
  9. SELLTicho Barry, CHIEF MEDICAL OFFICER sold Jul 1, 2026 7,228 shares 2 legs combined 10b5-1 plan (scheduled) filing $236K
  10. SELLAllan Jonathan, GENERAL COUNSEL & CORP SEC sold Jun 16, 2026 1,457 shares 10b5-1 plan (scheduled) filing $44K

Planned sales · SEC Form 144

Notice given

A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice

  1. EDWARD KAYE filed Oct 21, 2026 Former Affiliate 1,496,042 shares planned sale date 10/21/2026 filing $38.4M
  2. JONATHAN D ALLAN filed Oct 2, 2026 Officer 627 shares planned sale date 10/02/2026 filing $16K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. FMR LLC filed Nov 5, 2026 Schedule 13G/A passive 4,820,462 shares filing 7.5%
  2. BIOTECHNOLOGY VALUE FUND L P filed Sep 30, 2026 Schedule 13G passive filing 5.6%
  3. Lynx1 Capital Management LP filed Aug 14, 2026 Schedule 13G/A passive filing 6.5%
  4. The Toronto-Dominion Bank filed Aug 12, 2026 Schedule 13G/A passive filing 4.9%
  5. FMR LLC filed Aug 6, 2026 Schedule 13G/A passive 5,313,100 shares filing 8.5%

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Results of operations and financial condition filing Oct 29, 2026
  2. Departure or appointment of directors or officers filing Sep 25, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.